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Children with relapsed or refractory solid tumors face dismal prognoses, and novel therapies are desperately
needed. Allogeneic hematopoietic cell transplantation (HCT) offers potential for cell-based therapy, but the
toxicity of myeloablation limits this approach in heavily pretreated patients. We sought to determine the
feasibility of HCT in a cohort of 24 children with incurable solid tumors using human leukocyte antigene
matched sibling or unrelated donors and a minimal conditioning regimen. Before stem cell infusion, all
patients received 3 daily doses of 30 mg/m2 ﬂudarabine followed by 2 Gy of total body irradiation. Hema-
topoietic cell recovery was rapid and reliable. Median time to neutrophil engraftment was 13.5 days for
sibling donors and 12 days for unrelated donors. Donor lymphocyte infusions were used safely in 4 patients,
all of whom had either improved chimerism or apparent tumor response. Graft-versus-host disease was
comparable across donor sources and did not affect survival. Relapse remains a substantial barrier, although
objective graft-versus-tumor effect was observed in several patients. Four patients with detectable disease
before HCT achieved a complete response for at least 30 days after HCT, and two remain long-term survivors.
Three patients were in complete response before HCT and remained in remission for 3, 6, and 74 months after
HCT. Early disease response was associated with improved survival. Allogeneic HCT using this conditioning
regimen offers a potential platform for novel immunotherapies.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although substantial progress has been made in the
treatment of pediatric malignancies, the prognosis for chil-
dren with solid tumors has lagged behind that of acute
leukemia [1]. Those with relapsed or refractory disease have
exceptionally poor outcomes. Recurrent Ewing sarcoma
and rhabdomyosarcoma are fatal in more than 80% of cases
[2,3]. Children with metastatic or persistently unresectable
hepatoblastoma have similarly dismal prognoses [4].
Relapsed neuroblastoma is generally considered to be
beyond salvage [5]. Even malignancies such as lymphoma
and Wilms tumor, which may have favorable prognoses at
ﬁrst relapse, have markedly decreased survival with che-
morefractory disease [6,7]. Autologous stem cell trans-
plantation (ASCT) offers an option for some patients,
although success is limited [8-10]. Along with the risk of
transplantation-related mortality [11], disease recurrence
primarily limits the effectiveness of this approach [12].
Tumor contamination of autologous stem cell grafts is
frequent, and purging does not improve survival [13]. Chil-
dren who fail autologous transplantation have few options
and face dismal prognoses.
The effectiveness of cell-mediated cytotoxicity against
leukemia has long been recognized [14,15], perhaps best
demonstrated by reduced-intensity hematopoietic cell
transplantation (HCT) conditioning regimens that exploitdgments on page 296.
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chemotherapy [16]. There is also evidence for potential
graft-versus-tumor (GVT) effects in a number of pediatric
solid tumors [17-21]. Children with relapsed or refractory
solid tumors represent a heavily pretreated cohort facing
very high-risk malignancies. Reduced-intensity conditioning
(RIC) transplantation may offer the antitumor beneﬁt of
allografting without myeloablation, the excessive treatment-
related toxicity of which can potentially abrogate the beneﬁt
afforded by GVT.
Allogeneic HCT does not carry the risk of graft contam-
ination with tumor cells and offers a substantial platform
for additional cell therapy, such as donor lymphocyte
infusions (DLI) and immunotherapy for purposes of tumor
control [22]. Although allogeneic HCT is increasing among
adult solid tumor patients [23], HCT for children with
solid tumors has not been extensively described, especially
using an RIC approach. Early allogeneic HCT efforts with
myeloablative conditioning offered no advantage compared
with autologous grafts, largely because of complications
such as graft-versus-host disease (GVHD) and other
regimen-related toxicities [24]. However, transplantation-
related mortality has been reduced signiﬁcantly in
modern pediatric HCT, even with unrelated or hap-
loidentical donors [25]. Further, children not eligible for
myeloablative HCT can be successfully transplanted
using RIC [26]. We evaluated the feasibility of treating
children with relapsed or refractory solid tumors with
allogeneic HCT using a minimal conditioning regimen and
a matched sibling donor (MSD) or a matched unrelated
donor (MUD).Transplantation.
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Patients
Between March 2001 and July 2008, 24 patients were accrued to the
St. Jude Children’s Research Hospital (St. Jude) STSIB protocol in Memphis,
Tennessee. The protocol recruited patients to two strata: 12 patients
transplanted using an MSD and 12 transplanted with an MUD. The protocol
was approved by the St. Jude Institutional Review Board, and written
informed consent was obtained from all patients and their families. The
study was completed on September 30, 2010, and both survivors had at least
1 year of follow-up, including over 5 years since HCT. Two patients treated
on this protocol were reported previously [27,28].
Patients 21 years old or younger with a histologically conﬁrmed solid
malignancy including lymphoma, for which standard curative therapy had
failed or was unavailable, were eligible for the study. Children with primary
brain tumors were not eligible. Detectable disease at the time of trans-
plantationwas not required. All patients required either an available human
leukocyte antigen (HLA) identical sibling or a 6/6 HLA-matched unrelated
donor. Both bonemarrow and peripheral blood apheresis were acceptable as
hematopoietic stem cell sources. Exclusion criteria included an estimated
life expectancy of less than 8 weeks and autologous transplantation in the
preceding 3 months. Prior radiation therapy was permissible, but those
patients whose prior irradiation resulted in the inability to tolerate the
prescribed radiation dose for this protocol were not enrolled. Severe infec-
tion at the time of enrollmentwas also not allowed. Organ-speciﬁc exclusion
criteria included glomerular ﬁltration rate <40 mL/min/1.73 m2, direct
bilirubin >5 mg/dL, or serum glutamic pyruvic transaminase >500 U/L.
Female patients were also excluded for pregnancy or lactation.
HLA Typing, Donor Selection, and Chimerism
Donorerecipient pairs were selected based on HLA typing performed at
St. Jude. All participants reported in this study were evaluated for HLA
matching using family studies. HLAwas typed using high-resolution at HLA-
A, -B, -C, -DRB1, and -DQB1 speciﬁcities. Peripheral whole blood chimerisms,
performed using variable nucleotide tandem repeat polymerase chain
reaction, were determined at approximately weekly intervals beginning at
day þ14 until day þ100 and then approximately monthly for all patients
who remained on study.
Treatment Protocol
The same conditioning regimen was used for all patients, regardless of
donor type. On days 4 to 2, patients received ﬂudarabine at an intrave-
nous dose of 30 mg/m2 once daily. On day 0, patients were treated with
a single fraction of 2 Gy total body irradiation, followed by donor hemato-
poietic stem cell infusion. Granulocyte colony-stimulating factoremobilized
peripheral blood stem cells, collected via apheresis, were the preferred stem
cell source and were collected from sibling donors who were 16 years of
age, as per institutional guidelines. Sibling donors <16 years old underwent
bone marrow harvest. Nine of 12 patients in the MSD group received bone
marrow as a stem cell source. The remaining 3 patients received a peripheral
blood stem cell apheresis product. Unrelated donor requests were done in
accordance with the guidelines of the National Marrow Donor Program. In
the MUD group, 4 of 12 patients received a marrow product, and 8 received
a peripheral blood stem cell apheresis product.
GVHD prophylaxis consisted ofmycophenolatemofetil and cyclosporine A.
Mycophenolate mofetil was started on day 0 within 6 hours after the stem cell
infusion at a dose of 15 mg/kg/dose twice daily. Mycophenolate mofetil was
continued until approximately dayþ27. Cyclosporine Awas started at a dose of
2 mg/kg/dose intravenously every 12 hours on days 1. Beginning on day þ1,
dosingwas changed to 1mg/kg/dose intravenously every 12 hours or 4mg/kg/
dose by mouth every 12 hours. Doses were then adjusted to maintain thera-
peutic levels based on regular bloodmonitoring. For those patientswith 90% to
100% donor chimerism at approximately day þ35, cyclosporine A was
continued at a therapeutic level until approximately day þ60. Cyclosporine A
was then tapered by 25% every 5 days until discontinued. For patients with
<90% donor chimerism around day þ35, cyclosporine A was tapered more
rapidly and discontinued by approximately day þ50. Patients with donor
chimerism persistently <90% after withdrawal of immune suppression for 14
days or patients with stable or progressive disease were eligible for DLI if they
were free of clinical GVHD.
All patients received supportive care according to standard institutional
policies and procedures, including regular outpatient follow-up with
physical examination and laboratory testing. In addition to appropriate viral,
fungal, and Pneumocystis prophylaxis, patients were monitored weekly by
polymerase chain reaction assay for cytomegalovirus, Epstein-Barr virus,
and adenovirus as well as by galactomannan assay for Aspergillus. Gran-
ulocyte colony-stimulating factor was not routinely given or required by
protocol, but it was allowed intermittently at a dose of 5 mg/kg/day to
maintain an absolute neutrophil count of at least 500/mm3.The primary study endpoint was the induction of stable mixed or full-
donor hematopoietic chimerism using a minimal-intensity conditioning
regimen in a heavily pretreated cohort of pediatric solid tumor patients.
Acute and chronic GVHD was graded using the Seattle criteria [29,30], and
toxicities were determined using the National Cancer Institute Common
Toxicity Criteria, version 2.0, both institutional standards at the time of data
collection. Tumor response evaluations were performed at approximately
day þ30 and day þ60 for all surviving patients. Those patients with no
detectable disease by any modality were designated as complete response
(CR). Other deﬁnitions of tumor responses were responsive disease, deﬁned
as>50% regression of all tumor masses; progressive disease (PD), deﬁned as
an increase of 25% in the size of any tumor mass; and stable disease (SD),
designated to those patients who failed to qualify for either responsive
disease or PD.
Study Design and Statistical Analysis
The sample size of 12 patients for each stratum was chosen for
preliminary evaluation of successful induction of mixed or full-donor
chimerism. Stopping rules were in place for more than 2 failures in each
stratum, giving conﬁdence intervals of (0.52, 0.98), (0.62, 1.0), and (0.74, 1.0)
for 10, 11, or 12 successes, respectively. The MSD and MUD groups were
analyzed separately, and differences between donor groups were compared
by Fisher’s exact test. Kaplan-Meier estimates were used to evaluate overall
and event-free survival. The log-rank (Mantel-Cox) test was used to
compare survival function of different groups.
RESULTS
Patient Information
Characteristics of the 24 patients enrolled are detailed in
Table 1. Patient diagnoses included Ewing sarcoma family of
tumors (n ¼ 3), Hodgkin lymphoma (n ¼ 3), non-Hodgkin
lymphoma (n ¼ 1), hepatoblastoma (n ¼ 2), melanoma
(n¼ 1), neuroblastoma (n¼ 7), rhabdoid renal tumor (n¼ 1),
rhabdomyosarcoma (n ¼ 4), and Wilms tumor (n ¼ 2). All
patients were considered incurable with available therapy
and were heavily pretreated. Sixteen patients had received
prior myeloablative therapy; 6 of 12 patients who received
anMSD transplantation and 8 of 12 patients who received an
MUD transplantation had one previous ASCT. One additional
patient in each group had two prior ASCTs. Only three
patients had no detectable disease at the time of enrollment.
All others were either in relapse after prior remission or
refractory to all previous therapy. Themedian age of theMSD
and MUD recipients was 14 and 8 years old, respectively.
Twenty of 24 patients were white, including all 12 patients in
the MUD group. Patients 1, 2, and 8 were African American,
and patient 10 was of mixed ethnicity. All patients received
ﬂudarabine as an outpatient and were hospitalized on day
0 for total body irradiation and stem cell infusion. Most
patients (n ¼ 20) were discharged the following day. Three
patients were hospitalized 4 days, and 1 was an inpatient for
16 days. Median and mean lengths of initial hospitalization
were 2 and 2.8 days, respectively.Engraftment, Chimerism, and Additional Cell Product
Infusion
A summary of neutrophil and platelet recovery, separated
by donor type, is shown in Figure 1. The graphs depict the
percentage of patients achieving neutrophil and platelet
recovery, as indicated by an absolute neutrophil count500/
mm3 and platelet count 50,000/mm3. The median time to
neutrophil recovery was 13.5 days (0e20) for those with
sibling donors and 12 days (0e16) for unrelated donors. The
median time to recovery to a platelet count of 20,000/mm3
was 0 days for both groups. Thus, platelet recovery was
additionally evaluated using a threshold of 50,000/mm3.
Median time to this level was 7.5 days (0e33) for those
children with sibling donors and 16 days (0e36) for 11 of 12
Table 1
Patient and Transplantation Characteristics with Disease Staging










Days to PD Patient
Outcome
Matched sibling donors
1 12.6 NB REF No Marrow SD PD 48 DPD
2 13.4 NB REF Yes Marrow PD SD 28 DPD
3 7.7 WT REL1 No Marrow PD PD 27 DPD
4 17.6 RMS REL2 Yes Blood PD SD 28 DPD
5 14.6 Melanoma REF No Blood SD SD 143 DPD
6 17.3 Rhabdoid REL1 No Marrow CR PD 75 DPD
7 17.9 HL REL3 Yes Marrow SD CR N/A Alive
8 5.8 NB REL1 Yes Marrow SD PD 62 DPD
9 13.0 ESFT REL1 Yes Marrow SD SD 107 DPD
10 16.2 RMS REF Yes* Blood SD PD 71 DPD
11 12.3 ESFT REF No Marrow CR CR N/A Alive
12 17.7 HL CR4 Yes Marrow CR CR 115 DPD
Matched unrelated donors
13 20.7 NHL REL2 Yes Blood N/A N/A 15 DPD
14 10.2 HBL REL3 Yes Blood SD PD 58 DPD
15 6.3 NB REF Yes Marrow SD PD 65 DPD
16 21.2 HL CR5 Yes* Blood CR CR N/A DNED
17 8.6 NB REL1 Yes Blood SD SD 180 DPD
18 20.4 RMS REL2 No Blood CR CR N/A DNED
19 8.1 NB CR2 Yes Marrow CR CR 187 DPD
20 14.1 ESFT REL2 Yes Blood CR CR 175 DPD
21 3.2 RMS REL1 No Blood SD SD 195 DPD
22 7.7 NB REL1 Yes Marrow SD SD 276 DPD
23 7.5 WT REL1 Yes Marrow PD N/A 22 DPD
24 4.1 HBL REF No Blood PD PD 14 DPD
REF indicates primary refractory; REL, relapse with number; CR, complete response with number; HSC, hematopoietic stem cell; SD, stable disease; PD,
progressive disease; DPD, died from progressive disease; DNED, died with no evidence of disease; ESFT, Ewing sarcoma family of tumors; HL, Hodgkin
lymphoma; NHL, non-Hodgkin lymphoma; HBL, hepatoblastoma; NB, neuroblastoma; RMS, rhabdomyosarcoma; WT, Wilms tumor.
Time to progression is given as days after transplantation.
* Patient had 2 prior ASCT.
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died (patient 13) at day þ15 before platelet count reached
50,000/mm3.
Figure 2 summarizes the percentage of patients achieving
various levels of whole blood chimerism, according to their
donor source, at informative time points. Patient 13, who
rapidly died from progressive disease, was not evaluated for
donor chimerism at any time point. All tested patients had
detectable donor chimerism after 2 weeks. Twenty-one of 24
patients (89%) achieved a high level of chimerism (75%) by
1 month, and surviving patients generally maintained thatFigure 1. Hematopoietic cell recovery by donor. Graphs show percentage of patients a
count recovery to 50,000/mm3.chimerism at subsequent time points. Only one patient
(patient 2) who had marrow-inﬁltrating neuroblastoma
declined below 75% donor chimerism after reaching that
level. Twenty patients were followed beyond day þ100.
Eighteen of 20 patients maintained 100% donor chimerism,
including patient 7, who remains 100%. Patient 6 fell to 95%
donor shortly before death due to progressive disease,
whereas patient 2 continues to have a stably mixed chime-
rism of approximately 95% donor.
Four patients transplanted with an MSD received DLI.
Patient 2 received a single DLI of 2.18  106 CD3þ cells/kgchieving (A) absolute neutrophil count recovery to 500/mm3 and (B) platelet
Figure 2. Percentage of whole blood donor chimerism. SIB indicates matched sibling donor; MUD, matched unrelated donors. Averaged time points are used in the
x-axis (2 weeks [days 11e17, median 14], 1 month [days 26e34, median 31], 2 months [days 55e64, median 61.5], and 100 days [95e123, median 101]).
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5  106 CD3þ cells/kg on day þ63, and the second was
10  106 CD3þ cells/kg on day þ110. Both patients had
temporary improvements in their chimerism with DLI that
later reverted with disease progression. Patient 12 received
two DLIs, each dosed at 10  106 CD3þ cells/kg. The ﬁrst DLI
on day þ137 converted her chimerism from 98% to 100%,
where it remained until her eventual relapse, including
before and after her second DLI on day þ182. Patient 5 also
received two DLI for disease progression with a stable 100%
chimerism: one at 5  106 CD3þ cells/kg on day þ169 fol-
lowed by another at 45.83  106 CD3þ cells/kg on day þ391.
All DLI were tolerated without GVHD or other adverse events
in all patients. Supplemental Table 1 contains additional
details regarding cell content of initial stem cell product.Figure 3. Overall and event-free survival. (A) Overall survival by donor group, expre
(sibling) group and 280 days in the MUD (unrelated) group. Log-rank test P ¼ .4215. (
Events include death from any cause and receipt of nonprotocol therapy for progressiv
the MUD group. Log rank test P ¼ .6669. (C) Event-free survival by pretransplantatio
P ¼ .2200 refractory disease vs CR, P ¼ .4089. (D) Event-free survival by tumor stage at
CR, P ¼ .0198.Tumor Response
All surviving patients were evaluated for disease response
at day þ30 (n ¼ 23) and again at day þ60 (n ¼ 22). All
responses were graded as PD, SD, or CR. Table 1 includes
staging results as well as time to progression. One patient
with relapsed disease died before day þ30 evaluation, and
another died between day þ30 and day þ60 evaluations.
Among the childrenwho progressed by dayþ30, nonewas in
CR at dayþ60, and nonewas an eventual long-term survivor.
For the 11 children with disease stabilization at the ﬁrst
evaluation, 5 continued to have tumor control at day þ60.
Seven patients were in CR at day þ30. Six remained in CR at
the next evaluation, whereas only 1 had progressive disease.
All 3 patients in CR before transplantation remained without
evidence of disease at both evaluations.ssed as days after transplantation. Median overall survival 314 days in the SIB
B) Event-free survival by donor group, expressed as days after transplantation.
e disease. Median event-free survival 211 days in the SIB group and 254 days in
n disease status. Log-rank test for relapsed disease vs complete response (CR),
day þ30. Log-rank test for stable disease vs CR, P ¼ .432; progressive disease vs
Table 2







Total (%) P Value
Patient outcome
Death from disease 10 (83) 10 (83) 20 (83) 1.0
Death with NED* d 2 (17) 2 (8)
Alive disease-free 2 (17) d 2 (8)
Acute GVHD
Grade 1 or 2 3 (25) 4 (33) 7 (29) 1.0
Grade 3 or 4 2 (17) 6 (50) 8 (33) 0.19
Chronic GVHD
Limited 1 (8) 3 (25) 4 (17) 0.59
Extensive 3 (25) 3 (25) 7 (29) 1.0
* Both died from aspergillosis complicating GVHD with no evidence of
disease (NED).
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rated by donor source as well as by disease status. Twenty-
two patients (92%) in this heavily pretreated cohort ulti-
mately died from their underlying malignancy. Nine patients
came off study to pursue additional therapy, all of whom
died from progressive disease. There was no statistically
signiﬁcant difference in survival among donor types. Two
patients remain long-term survivors. Patient 7 had multiply
relapsed Hodgkin lymphoma with biopsy-conﬁrmed malig-
nant pulmonary nodules at the time of HCT, only partially
responsive to salvage chemotherapy. Patient 11 completed
intended therapy for metastatic Ewing sarcoma family of
tumors, yet was found to have a persistent positron emission
tomographyeavid mass adjacent to her previous primary
tumor. Both patients are well with no evidence of disease.
Of the patients that received DLI, patients 2 and 5 had
disease progression despite DLI. Patient 3 had progression
after her ﬁrst DLI but had a mixed response after her second
DLI. Patient 12 had multiply relapsed Hodgkin lymphoma
that was in fourth CR at the time of HCT. Approximately 3
months after transplantation, she was found to have biopsy-
conﬁrmed recurrence in a thoracic vertebra that was treated
with focal radiation and her second DLI. For almost 2 years,
she was disease-free, until an asymptomatic relapse was
detected on routine disease follow-up as a hepatic nodule.
She received salvage chemotherapy but ultimately died 768
days after transplantation.
GVHD and Toxicity
A summary of GVHD as well as survival by donor source is
contained in Table 2. Acute GVHD occurred in 15 patients,
with low-grade (I or II) disease occurring in 3 patients
transplanted using sibling donors and 4 who were trans-
planted using unrelated donors. Six children in the MUD
group developed high-grade (III or IV) acute GVHD compared
with two children transplanted with sibling donors. There
were no statistical differences in rates of GVHD by donor
source. In addition, there was no difference in survival
among those who developed GVHD, as compared with those
who did not. Both long-term survivors are off all immuno-
suppressive medications and have no evidence of GVHD.
Patient-speciﬁc GVHD information is provided in
Supplemental Table 1. In this extensively treated population,
some grade IV toxicities occurred. Of these, the most
commonly recorded toxicities were asymptomatic labora-
tory abnormalities (ie, electrolytes, blood counts). Infectious
complications, most commonly catheter-related infection,
occurred in 6 patients.Two patients had their malignancy controlled but died
from infectious complications. Patient 16 had multiply
relapsed Hodgkin lymphoma that initially had a relatively
uncomplicated post-HCT course until an orthopedic proce-
dure incited signiﬁcant, progressive sclerodermatous chronic
GVHD approximately 18 months posttransplantation
requiring systemic corticosteroids and cyclosporine A.
Approximately 2 months after starting systemic immuno-
suppression, he presented with pulmonary aspergillosis
from which he died on day þ887. Patient 18 had relapsed
rhabdomyosarcoma whose post-HCT course was compli-
cated by signiﬁcant acute skin, liver, and gut GVHD as well as
pulmonary Aspergillus infection. Despite antifungal therapy,
she died from complications of disseminated aspergillosis on
day þ250.DISCUSSION
Increasingly intensive chemotherapy in modern treat-
ment protocols often leaves children affected by solid tumors
with signiﬁcant organ dysfunction [31,32]. Those that relapse
face further toxic therapy, including myeloablation with
ASCT [33]. Yet despite dose intensiﬁcation, cure rates remain
unacceptably low. With the impact of immunotherapy on
outcomes for high-risk neuroblastoma [34], there has been
renewed interest in novel solid tumor therapeutic
approaches that bypass drug resistance. Allogeneic HCT
offers the beneﬁt of sustained alloreactivity, but conven-
tional HCT approaches can be limited by toxicity. HCT using
RIC has been effectively used for adults who cannot tolerate
myeloablative therapy, and this study showed that a heavily
pretreated pediatric population could also tolerate HCT using
this approach.
The conditioning regimen was well tolerated, and
hematopoietic cell engraftment proved to be rapid and reli-
able. Combined with the ability to deliver the majority of the
therapy as an outpatient, this approach could considerably
decrease resource utilization, especially when compared
withmyeloablative HCT. All children had neutrophil recovery
within 3 weeks, and some were never neutropenic. Most
patients never developed thrombocytopenia below standard
transfusion thresholds. In addition, the average length of
hospitalization was less than 3 days. This compares quite
favorably with a current 31-day average admission for allo-
geneic transplantation at our institution. Sibling and unre-
lated donors were analyzed separately; no signiﬁcant
differences between these two groups were detected, either
in terms of toxicity or response, extending the feasibility of
this therapy to those patients without matched siblings.
Several mechanisms by which tumor cells may escape
endogenous immune surveillance have been proposed,
including altered antigen presentation and production of
immunosuppressive cytokines [35]. Immune escape
provides an important rationale for allogeneic HCT, where
donor-immune effector cells may recognize tumor cells that
host cells have spared. Unlike leukemia, where graft-versus-
leukemia has been well demonstrated, similar GVT effects in
pediatric solid tumors have been difﬁcult to consistently
establish, and few such studies have been reported. Few
tumor-speciﬁc antigens exist, and the mechanisms behind
GVT remain poorly understood. This is likely due to the
complex immunologic milieu within the tumor microenvi-
ronment, but tumor-inﬁltrating lymphocytes may play an
important role, both in tumor invasion and recruitment of
cytotoxic lymphocytes [36].
D.R. Shook et al. / Biol Blood Marrow Transplant 19 (2013) 291e297296The children in this study, representative of awide variety
of advanced pediatric tumors, were extremely high risk,
eligible only if no alternative curative therapy was available.
With little to no antineoplastic effect afforded by the
conditioning regimen, all observed tumor responses support
an active GVT effect. Four patients with evidence of disease
before HCT achieved CR, and the 3 patients in CR before HCT
remained so for 3, 6, and 74 months, respectively, after HCT.
Two long-term survivors continue to be followed, and they
are well without disease. Unfortunately, the two patients
who died from fatal opportunistic fungal infections also both
had no evidence of disease. Further strengthening the impact
of alloreactivity, 4 patients with matched sibling donors
received DLI, all with apparent clinical beneﬁt. The infusions
were well tolerated, and each patient had either improved
donor chimerism or tumor response after DLI. One patient
(patient 12) developed a distant recurrence associated with
mixed chimerism that was treated with only local irradiation
and DLI, yet she re-entered CR and had systemic disease
control with 100% chimerism for nearly 2 years. GVHD rates
were acceptable, and neither acute nor chronic GVHD
statistically affected survival.
Patient numbers were small, making it difﬁcult to deter-
mine the impact of disease burden at the time of HCT on
response or outcomes. However, other investigators using
RIC HCT for pediatric sarcomas have recently described
a survival beneﬁt in children with no detectable disease
before HCT [37]. One important observation was the impact
of early disease progression. Complete response at day þ30
imparted a statistically signiﬁcant increase in duration of
survival over those with progressive disease. Thus, this
subset of patients, representing approximately one-third of
the cohort, would have survived long enough to allow
subsequent novel consolidative therapy, such as cellular or
monoclonal antibody therapy [34]. Allogeneic HCT is
advantageous over ASCT in this regard, as donors can be
reapproached for additional cell products for disease
consolidation or to treat relapse. These cell products would
also be expected to have improved in vivo survival and
proliferation after allogeneic HCT, as compared with adop-
tive cellular therapy alone. Killer immunoglobulin-like
receptor (KIR) typing was not performed on patients in this
study, but the interaction between natural killer cell KIR and
target cell HLA has been shown to affect outcomes on allo-
geneic transplantation [38]. A similar prognostic beneﬁt to
KIR-HLAmismatch has also been described in the autologous
setting [39,40] as well as with immunocytokine therapy [41].
Even with the potential advantage of breaking self-tolerance
through chemotherapy, the full immunologic beneﬁt of ASCT
can only be realized in a subset of fortuitous patients with
appropriate natural killer cell reactivity. Allogeneic HCT
offers the opportunity to select a potentially more appro-
priate KIR-HLA mismatched donor.
In summary, this phase I study was able to demonstrate
the feasibility of allogeneic HCT in children with relapsed or
refractory solid tumors using HLA-matched sibling or unre-
lated donors and a minimal conditioning regimen. Although
some disease control was achieved, disease progression
remained the main cause of mortality. Improved biologic
understanding of the interactions between patient tumor
cells and donor immune effector cells may aid future studies.
Engraftment was excellent and offers the opportunity for
other cellular or antibody therapies, immune modulating
agents [42], or additional adoptive cellular therapy with
natural killer cells [43] or genetically modiﬁed T cells [44].ACKNOWLEDGMENTS
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